Diabetes and weight-loss medications, known as GLP-1 or incretin drugs, have taken the world by storm — especially the United States. Popularized by Ozempic, these treatments mimic gut hormones that regulate blood sugar and suppress appetite, making them highly sought after for their weight-loss effects. Popular name brands of these treatments include Novo Nordisk’s (NVO) Wegovy and Eli Lilly $LLY’s (LLY) Zepbound.
Sales of these drugs have skyrocket in recent years. According to Morgan Stanley $MS (MS) analysts, the global market for these medications could hit $105 billion by 2030. In the U.S. alone, the bank projects that around 31.5 million people — or nearly 10% of the population — will be using these treatments by 2035.
Still, the popularity and accessibility of GLP-1 medications vary greatly depending on the state.
Check out the state’s with the highest and lowest GLP-1 prescription rates, according to data from health analytics company PurpleLab:
1 / 9
Louisiana has a rate of 15.4 prescriptions per 1,000 residents.
2 / 9
Mississippi has a rate of 16.1 prescriptions per 1,000 residents.
3 / 9
Alaska has a rate of 17.5 prescriptions per 1,000 residents.
4 / 9
West Virginia has a rate of 18.9 prescriptions per 1,000 residents.
5 / 9
Kentucky has a rate of 20.7 prescriptions per 1,000 residents.
6 / 9
Hawaii has a rate of 4.3 prescriptions per 1,000 residents.
7 / 9
Wisconsin has a rate of 4.3 prescriptions per 1,000 residents.
8 / 9
Massachusetts has a rate of 4 prescriptions per 1,000 residents.
9 / 9
Rhode Island has a rate of 3.7 prescriptions per 1,000 residents.
